Expand OCUL Menu
OCUL MENU

OCUL Latest Press Releases

-- August 7, 2026 --

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- August 3, 2026 --

Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights Globe Newswire 7:00 AM

-- July 9, 2026 --

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- July 1, 2026 --

Ocular Therapeutix to Participate in July Scientific and Investor Conferences Globe Newswire 7:00 AM

-- June 22, 2026 --

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- June 17, 2026 --

Ocular Therapeutix Investor Day to Highlight U.S. FDA Alignment on AXPAXLI NDA with Submission Planned for Fourth Quarter 2026 Globe Newswire 8:45 AM

-- June 5, 2026 --

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- June 4, 2026 --

Ocular Therapeutix to Participate in Clinical Trials at the Summit 2026 Globe Newswire 7:00 AM

-- June 2, 2026 --

Ocular Therapeutix to Host Investor Day on June 17, 2026 Globe Newswire 7:00 AM

-- May 8, 2026 --

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- May 5, 2026 --

Ocular Therapeutix Reports First Quarter 2026 Financial Results and Business Highlights Globe Newswire 7:00 AM

-- April 29, 2026 --

Ocular Therapeutix Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI in Wet AMD Globe Newswire 7:00 AM

-- April 28, 2026 --

Ocular Therapeutix to Report First Quarter 2026 Financial Results on May 5, 2026 Globe Newswire 7:00 AM

-- April 27, 2026 --

Ocular Therapeutix to Participate in May Scientific and Investor Conferences Globe Newswire 7:00 AM

-- April 22, 2026 --

Ocular Therapeutix to Host Investor Day on June 17, 2026 Globe Newswire 7:00 AM

-- April 14, 2026 --

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

-- April 13, 2026 --

Ocular Therapeutix Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Globe Newswire 7:00 AM

-- April 1, 2026 --

Ocular Therapeutix to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes